Targeted Desialylation Overcomes Glyco-Immune Checkpoints and Potentiates the Anticancer Immune Response in Vivo

doi 10.26434/chemrxiv.8187146.v1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

In Vivo Silencing of A20 via TLR9-Mediated Targeted SiRNA Delivery Potentiates Antitumor Immune Response

PLoS ONE
Multidisciplinary
2015English

Platinum Derivatives Effects on Anticancer Immune Response

Biomolecules
BiochemistryMolecular Biology
2019English

The Blockade of Immune Checkpoints in Cancer Immunotherapy

Nature Reviews Cancer
Cancer ResearchOncology
2012English

Immune Checkpoints in Thymic Epithelial Tumors: Challenges and Opportunities

Immuno-Oncology Technology
2019English

Glyco-Immune Diagnostic Signatures and Therapeutic Targets of Mesothelioma

2013English

Concordance of Immune Checkpoints Within Tumor Immune Contexture and Their Prognostic Significance in Gastric Cancer

Molecular Oncology
Cancer ResearchMedicineOncologyGeneticsMolecular Medicine
2016English

Comprehensive Transcriptome Profiling in Elderly Cancer Patients Reveals Aging-Altered Immune Cells and Immune Checkpoints

International Journal of Cancer
Cancer ResearchOncology
2018English

Expression Patterns of Immune Checkpoints in Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2020English

Antibodies Targeted to TRAIL Receptor-2 and ErbB-2 Synergize in Vivo and Induce an Antitumor Immune Response

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy